These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 11729030)
41. Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Veerman SR; Schulte PF; Begemann MJ; de Haan L Pharmacopsychiatry; 2014 Nov; 47(7):231-8. PubMed ID: 25121994 [TBL] [Abstract][Full Text] [Related]
42. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435 [TBL] [Abstract][Full Text] [Related]
43. Methylphenidate challenge as a predictor of relapse in schizophrenia. Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506 [TBL] [Abstract][Full Text] [Related]
44. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Harvey PD; Napolitano JA; Mao L; Gharabawi G Int J Geriatr Psychiatry; 2003 Sep; 18(9):820-9. PubMed ID: 12949850 [TBL] [Abstract][Full Text] [Related]
45. All antipsychotics are equal, but some are more equal than others. Volavka J; Citrome L J Clin Psychiatry; 2009 Mar; 70(3):429-30. PubMed ID: 19317959 [No Abstract] [Full Text] [Related]
46. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345 [TBL] [Abstract][Full Text] [Related]
47. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. Kaneda Y; Jayathilak K; Meltzer H Psychiatry Res; 2010 Jun; 178(1):57-62. PubMed ID: 20452677 [TBL] [Abstract][Full Text] [Related]
48. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. Muscatello MR; Pandolfo G; Micò U; Lamberti Castronuovo E; Abenavoli E; Scimeca G; Spina E; Zoccali R; Bruno A J Clin Psychopharmacol; 2014 Feb; 34(1):129-33. PubMed ID: 24145221 [TBL] [Abstract][Full Text] [Related]
49. Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. Pandina G; Bilder R; Turkoz I; Alphs L Schizophr Res; 2013 Feb; 143(2-3):312-8. PubMed ID: 23276482 [TBL] [Abstract][Full Text] [Related]
50. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745 [TBL] [Abstract][Full Text] [Related]
51. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. Fusar-Poli P; Berger G J Clin Psychopharmacol; 2012 Apr; 32(2):179-85. PubMed ID: 22367656 [TBL] [Abstract][Full Text] [Related]
52. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176 [TBL] [Abstract][Full Text] [Related]
53. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Bodkin JA; Siris SG; Bermanzohn PC; Hennen J; Cole JO Am J Psychiatry; 2005 Feb; 162(2):388-90. PubMed ID: 15677608 [TBL] [Abstract][Full Text] [Related]
55. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Stauffer VL; Song G; Kinon BJ; Ascher-Svanum H; Chen L; Feldman PD; Conley RR Schizophr Res; 2012 Feb; 134(2-3):195-201. PubMed ID: 22019076 [TBL] [Abstract][Full Text] [Related]
56. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Daniel DG; Zimbroff DL; Potkin SG; Reeves KR; Harrigan EP; Lakshminarayanan M Neuropsychopharmacology; 1999 May; 20(5):491-505. PubMed ID: 10192829 [TBL] [Abstract][Full Text] [Related]
57. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054 [TBL] [Abstract][Full Text] [Related]
58. The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial. Weiser M; Levi L; Burshtein S; Chiriță R; Cirjaliu D; Gonen I; Yolken R; Davidson M; Zamora D; Davis JM Schizophr Res; 2019 Apr; 206():325-332. PubMed ID: 30455075 [TBL] [Abstract][Full Text] [Related]
59. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Frangou S; Lewis M; McCrone P Br J Psychiatry; 2006 Jan; 188():46-50. PubMed ID: 16388069 [TBL] [Abstract][Full Text] [Related]
60. Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods. Pawełczyk T; Grancow M; Kotlicka-Antczak M; Trafalska E; Gębski P; Szemraj J; Żurner N; Pawełczyk A BMC Psychiatry; 2015 May; 15():97. PubMed ID: 25934131 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]